{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:15:26Z","timestamp":1791504926153,"version":"4.3.4"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"International Cooperation Excellence Initiative"},{"DOI":"10.13039\/501100013365","name":"West China Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["139220012"],"award-info":[{"award-number":["139220012"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research and Development Project of Chengdu Science and Technology Bureau","award":["2022YF0501792SN"],"award-info":[{"award-number":["2022YF0501792SN"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Helicobacter pylori infection is a leading cause of chronic gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Consequently, H. pylori eradication is recommended as a primary prevention strategy for gastric cancer, even in asymptomatic individuals. However, the global rise in antibiotic resistance has led to increasing eradication failures, even with first-line bismuth quadruple therapies. Rifabutin, a rifamycin derivative, has shown promise as an alternative treatment option, both as a rescue therapy and even as first-line therapy, due to its potent bactericidal activity, high gastric concentration, and stability across a broad pH range. This review summarizes the efficacy and safety of rifabutin-containing H. pylori eradication regimens, as reported in various studies. We analyze the impact of rifabutin dosage, combinations with other antibiotics and gastric acid inhibitors, bismuth inclusion, therapy duration, and demographic factors on treatment efficacy and patient compliance. Furthermore, we review rifabutin resistance in H. pylori, including the underlying mechanisms. Future large-scale, multicenter clinical trials are needed to optimize rifabutin-containing H. pylori eradication regimens. These trials should focus on rifabutin dosing strategies, the incorporation of potassium-competitive acid blockers, evaluation of potential benefits from bismuth addition, and exploration of shorter, 7-day treatment durations. Establishing standardized susceptibility testing methods and clinical minimum inhibitory concentration breakpoints for rifabutin resistance is also important for a better understanding of its role in H. pylori treatment and for optimizing its use in both rescue and first-line therapies.<\/jats:p>","DOI":"10.1093\/infdis\/jiaf476","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:10:47Z","timestamp":1757679047000},"page":"S384-S396","source":"Crossref","is-referenced-by-count":1,"title":["Rifabutin-Containing Therapy for\n                    <i>Helicobacter pylori<\/i>\n                    Eradication: A Review"],"prefix":"10.1093","volume":"232","author":[{"given":"Jun-Peng","family":"Zhou","sequence":"first","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu, Sichuan ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University , Chengdu, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Kuo","family":"Yang","sequence":"additional","affiliation":[{"name":"Aviation Medical Appraisal Center, Civil Aviation Flight University of China , Guanghan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Healthcare-associated Infection Management, West China Second University Hospital of Sichuan University\/West China Women's and Children's Hospital , Chengdu ,","place":["China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education , Chengdu ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Tay","sequence":"additional","affiliation":[{"name":"Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Disease Research and Training, University of Western Australia Helicobacter pylori \u00a0 , Nedlands, WA ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-0192","authenticated-orcid":false,"given":"Mohammed","family":"Benghezal","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu, Sichuan ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University , Chengdu, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J","family":"Marshall","sequence":"additional","affiliation":[{"name":"Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Disease Research and Training, University of Western Australia Helicobacter pylori \u00a0 , Nedlands, WA ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu, Sichuan ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University , Chengdu, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3528-0448","authenticated-orcid":false,"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu, Sichuan ,","place":["China"]},{"name":"Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University , Chengdu, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2025112010502766100_jiaf476-B1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"2025112010502766100_jiaf476-B2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","article-title":"Global burden of gastric cancer attributable to Helicobacter pylori","volume":"136","author":"Plummer","year":"2015","journal-title":"Int J Cancer"},{"key":"2025112010502766100_jiaf476-B3","doi-asserted-by":"crossref","first-page":"e2118457","DOI":"10.1001\/jamanetworkopen.2021.18457","article-title":"Global incidence and mortality of gastric cancer, 1980\u20132018","volume":"4","author":"Wong","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025112010502766100_jiaf476-B4","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025112010502766100_jiaf476-B5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2023.10.013","article-title":"Helicobacter pylori treatment and gastric cancer risk after endoscopic resection of dysplasia: a nationwide cohort study","volume":"166","author":"Yoo","year":"2024","journal-title":"Gastroenterology"},{"key":"2025112010502766100_jiaf476-B6","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2025112010502766100_jiaf476-B7","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"2025112010502766100_jiaf476-B8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022","volume":"166","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"2025112010502766100_jiaf476-B9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025112010502766100_jiaf476-B11","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/gutjnl-2021-324032","article-title":"Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community","volume":"70","author":"Megraud","year":"2021","journal-title":"Gut"},{"key":"2025112010502766100_jiaf476-B12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12879-018-3099-4","article-title":"The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis","volume":"18","author":"Jaka","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2025112010502766100_jiaf476-B13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/ajg.2014.24","article-title":"The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America","volume":"109","author":"Camargo","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2025112010502766100_jiaf476-B14","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.14309\/ajg.0000000000001828","article-title":"Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021: a systematic review and meta-analysis","volume":"117","author":"Ho","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2025112010502766100_jiaf476-B15","doi-asserted-by":"crossref","first-page":"e12873","DOI":"10.1111\/hel.12873","article-title":"Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing","volume":"27","author":"Li","year":"2022","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B16","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1093\/clinids\/5.Supplement_3.S402","article-title":"History of the development of rifampin","volume":"5 Suppl 3","author":"Sensi","year":"1983","journal-title":"Rev Infect Dis"},{"key":"2025112010502766100_jiaf476-B17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","article-title":"Antimicrobial activity of rifabutin","volume":"22 Suppl 1","author":"Kunin","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2025112010502766100_jiaf476-B18","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1099\/ijs.0.02901-0","article-title":"Reclassification of Amycolatopsis mediterranei DSM 46095 as Amycolatopsis rifamycinica sp. nov","volume":"54","author":"Bala","year":"2004","journal-title":"Int J Syst Evol Microbiol"},{"key":"2025112010502766100_jiaf476-B19","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","article-title":"The clinical pharmacokinetics of rifabutin","volume":"22 Suppl 1","author":"Blaschke","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2025112010502766100_jiaf476-B20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1086\/513753","article-title":"Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida","volume":"25","author":"May","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2025112010502766100_jiaf476-B21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2025112010502766100_jiaf476-B22","doi-asserted-by":"crossref","first-page":"e12451","DOI":"10.1111\/hel.12451","article-title":"Molecular characterization of Helicobacter pylori resistance to rifamycins","volume":"23","author":"Hays","year":"2018","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1348-0421.1996.tb03303.x","article-title":"Different rifampicin inactivation mechanisms in Nocardia and related taxa","volume":"40","author":"Tanaka","year":"1996","journal-title":"Microbiol Immunol"},{"key":"2025112010502766100_jiaf476-B24","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1073\/pnas.0711939105","article-title":"Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr","volume":"105","author":"Baysarowich","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112010502766100_jiaf476-B25","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1128\/AAC.01166-12","article-title":"Characterization of a rifampin-inactivating glycosyltransferase from a screen of environmental actinomycetes","volume":"56","author":"Spanogiannopoulos","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112010502766100_jiaf476-B26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B27","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1128\/AAC.43.5.1072","article-title":"In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657","volume":"43","author":"Akada","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112010502766100_jiaf476-B28","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-3565(25)21290-3","article-title":"In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats","volume":"279","author":"Koudriakova","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"2025112010502766100_jiaf476-B29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/antibiotics9100685","article-title":"Rifabutin-containing triple therapy (RHB-105) for eradication of Helicobacter pylori: randomized ERADICATE Hp trial","volume":"9","author":"Kalfus","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025112010502766100_jiaf476-B30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/M19-3734","article-title":"Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial","volume":"172","author":"Graham","year":"2020","journal-title":"Ann Intern Med"},{"key":"2025112010502766100_jiaf476-B31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pathogens10010015","article-title":"Rifabutin for the treatment of Helicobacter pylori infection: a review","volume":"10","author":"Gisbert","year":"2020","journal-title":"Pathogens (Basel)"},{"key":"2025112010502766100_jiaf476-B32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJM199807023390116","article-title":"Treatment of antibiotic-resistant Helicobacter pylori","volume":"339","author":"Perri","year":"1998","journal-title":"N Engl J Med"},{"key":"2025112010502766100_jiaf476-B33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1365-2036.2000.00719.x","article-title":"Rifabutin-based \u2018rescue therapy\u2019 for Helicobacter pylori infected patients after failure of standard regimens","volume":"14","author":"Perri","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B34","first-page":"58","article-title":"Randomized study of two \u201crescue\u201d therapies for Helicobacter pylori-infected patients after failure of standard triple therapies","volume":"96","author":"Perri","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"2025112010502766100_jiaf476-B35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2036.2003.01459.x","article-title":"Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection","volume":"17","author":"Wong","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1523-5378.2003.00128.x","article-title":"Rescue\u2019 therapy with rifabutin after multiple Helicobacter pylori treatment failures","volume":"8","author":"Gisbert","year":"2003","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.dld.2003.09.018","article-title":"Empirical Helicobacter pylori \u201crescue\u201d therapy after failure of two eradication treatments","volume":"36","author":"Gisbert","year":"2004","journal-title":"Dig Liver Dis"},{"key":"2025112010502766100_jiaf476-B38","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2036.2005.02687.x","article-title":"Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin","volume":"22","author":"Gisbert","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2036.2006.02793.x","article-title":"Efficacy and safety of rifabutin-containing \u2018rescue therapy\u2019 for resistant Helicobacter pylori infection","volume":"23","author":"Borody","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B40","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1365-2036.2006.03149.x","article-title":"Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures","volume":"24","author":"Gisbert","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-230X-7-31","article-title":"Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate Helicobacter pylori infection","volume":"7","author":"Navarro-Jarabo","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"2025112010502766100_jiaf476-B42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2036.2007.03573.x","article-title":"Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients","volume":"27","author":"Gisbert","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1523-5378.2007.00588.x","article-title":"One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"13","author":"Miehlke","year":"2008","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B44","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.12089","article-title":"Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations","volume":"36","author":"Tay","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B45","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2036.2012.05053.x","article-title":"Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cgh.2012.12.007","article-title":"Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection","volume":"11","author":"Fiorini","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025112010502766100_jiaf476-B47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/hel.12147","article-title":"Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori","volume":"19","author":"Lim","year":"2014","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B48","doi-asserted-by":"crossref","first-page":"367","DOI":"10.15403\/jgld.2014.1121.234.qrth","article-title":"Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens","volume":"23","author":"Ierardi","year":"2014","journal-title":"J Gastrointestin Liver Dis"},{"key":"2025112010502766100_jiaf476-B49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10620-014-3365-2","article-title":"Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy","volume":"60","author":"Gisbert","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2025112010502766100_jiaf476-B50","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/2050640615618043","article-title":"Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study","volume":"4","author":"Mori","year":"2016","journal-title":"United European Gastroenterol J"},{"key":"2025112010502766100_jiaf476-B51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/hel.12296","article-title":"Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies","volume":"21","author":"Ciccaglione","year":"2016","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ygh2.372","article-title":"Empirical Helicobacter pylori rescue therapy: an 18-year single-centre study of 1200 patients","volume":"1","author":"Burgos-Santamar\u00eda","year":"2019","journal-title":"GastroHep"},{"key":"2025112010502766100_jiaf476-B53","doi-asserted-by":"crossref","first-page":"e12557","DOI":"10.1111\/hel.12557","article-title":"Helicobacter pylori antimicrobial resistance during a 5-year period (2013\u20132017) in northern Spain and its relationship with the eradication therapies","volume":"24","author":"Cosme","year":"2019","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B54","doi-asserted-by":"crossref","first-page":"e12719","DOI":"10.1111\/hel.12719","article-title":"Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: a prospective single-arm study","volume":"25","author":"Hirata","year":"2020","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B55","doi-asserted-by":"crossref","first-page":"e12844","DOI":"10.1111\/hel.12844","article-title":"Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance","volume":"26","author":"Lee","year":"2021","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B56","doi-asserted-by":"crossref","first-page":"e12830","DOI":"10.1111\/hel.12830","article-title":"Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-exploratory study","volume":"26","author":"Gunaratne","year":"2021","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B57","doi-asserted-by":"crossref","first-page":"e12900","DOI":"10.1111\/hel.12900","article-title":"Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen","volume":"27","author":"Inokuchi","year":"2022","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B58","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1002\/hsr2.780","article-title":"Comparison of eradication rates of moxifloxacin-rifabutin triple therapy and bismuth quadruple therapy as second-line regimens in patients with peptic ulcers","volume":"5","author":"Lee","year":"2022","journal-title":"Health Sci Rep"},{"key":"2025112010502766100_jiaf476-B59","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/infdis\/jiad114","article-title":"Rifabutin-containing triple therapy versus bismuth quadruple therapy for Helicobacter pylori rescue treatment: a multicenter, randomized controlled trial","volume":"228","author":"Chen","year":"2023","journal-title":"J Infect Dis"},{"key":"2025112010502766100_jiaf476-B60","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.3390\/jcm13133774","article-title":"Single-arm, prospective, interventional study of Helicobacter pylori eradication rescue therapy with rifabutin, metronidazole, and vonoprazan","volume":"13","author":"Sue","year":"2024","journal-title":"J Clin Med"},{"key":"2025112010502766100_jiaf476-B61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-230X-1-7","article-title":"Efficacy of Helicobacter pylori eradication therapies: a single centre observational study","volume":"1","author":"Beales","year":"2001","journal-title":"BMC Gastroenterol"},{"key":"2025112010502766100_jiaf476-B62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2036.2004.02210.x","article-title":"Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients","volume":"21","author":"Qasim","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B63","first-page":"303","article-title":"Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection","volume":"24","author":"van Zanten","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"2025112010502766100_jiaf476-B64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004836-200010000-00007","article-title":"Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience","volume":"31","author":"Bock","year":"2000","journal-title":"J Clin Gastroenterol"},{"key":"2025112010502766100_jiaf476-B65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.dld.2004.09.008","article-title":"Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin","volume":"37","author":"Toracchio","year":"2005","journal-title":"Dig Liver Dis"},{"key":"2025112010502766100_jiaf476-B66","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2036.2006.02993.x","article-title":"Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"24","author":"Miehlke","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B67","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-5378.2006.00407.x","article-title":"Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole","volume":"11","author":"Marzio","year":"2006","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B68","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1440-1746.2006.04375.x","article-title":"Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments","volume":"22","author":"Gonz\u00e1lez Carro","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"2025112010502766100_jiaf476-B69","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1365-2036.2007.03531.x","article-title":"The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice","volume":"26","author":"Van der Poorten","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.dld.2009.05.013","article-title":"Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment","volume":"42","author":"Sacco","year":"2010","journal-title":"Dig Liver Dis"},{"key":"2025112010502766100_jiaf476-B71","first-page":"131","article-title":"Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice","volume":"19","author":"Zullo","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"2025112010502766100_jiaf476-B72","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3748\/wjg.v23.i18.3367","article-title":"Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance","volume":"23","author":"Cosme","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2025112010502766100_jiaf476-B73","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4166\/kjg.2017.69.2.109","article-title":"Rifabutin-based fourth and fifth-line rescue therapy in patients with for Helicobacter pylori eradication failure","volume":"69","author":"Sung","year":"2017","journal-title":"Korean J Gastroenterol"},{"key":"2025112010502766100_jiaf476-B74","first-page":"198","article-title":"Seven-day genotypic resistance-guided triple Helicobacter pylori eradication therapy can be highly effective","volume":"31","author":"Papastergiou","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2025112010502766100_jiaf476-B75","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/jcm8020199","article-title":"Rifabutin-based rescue therapy for Helicobacter pylori eradication: a long-term prospective study in a large cohort of difficult-to-treat patients","volume":"8","author":"Ribaldone","year":"2019","journal-title":"J Clin Med"},{"key":"2025112010502766100_jiaf476-B76","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12876-020-01370-4","article-title":"Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains","volume":"20","author":"Kuo","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"2025112010502766100_jiaf476-B77","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2036.2001.00909.x","article-title":"Rifabutin-based Helicobacter pylori eradication \u2018rescue therapy\u2019","volume":"15","author":"Canducci","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B78","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MCG.0000000000000540","article-title":"Rifabutin triple therapy is effective in patients with multidrug-resistant strains of Helicobacter pylori","volume":"52","author":"Fiorini","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"2025112010502766100_jiaf476-B79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/antibiotics9030121","article-title":"Antibiotic resistance and therapy outcome in H. pylori eradication failure patients","volume":"9","author":"Saracino","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025112010502766100_jiaf476-B80","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejim.2020.06.029","article-title":"Rifabutin-based triple therapy or bismuth-based quadruple regimen as rescue therapies for Helicobacter pylori infection","volume":"81","author":"Saracino","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2025112010502766100_jiaf476-B81","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MCG.0000000000001457","article-title":"Rescue therapies for Helicobacter pylori infection in foreign patients treated in Italy","volume":"55","author":"Saracino","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"2025112010502766100_jiaf476-B82","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/apt.17526","article-title":"Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection","volume":"58","author":"Howden","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B83","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jpn3.12242","article-title":"Impact of medication dosage on Helicobacter pylori eradication rates among pediatric patients","volume":"79","author":"Andrews","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025112010502766100_jiaf476-B84","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1111\/bcp.14739","article-title":"Pharmacokinetics of amoxicillin in obese and nonobese subjects","volume":"87","author":"Soares","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025112010502766100_jiaf476-B85","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1046\/j.1365-2036.2000.00837.x","article-title":"Review article: the control of gastric acid and Helicobacter pylori eradication","volume":"14","author":"Sachs","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B86","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","article-title":"1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases","volume":"335","author":"Hori","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"2025112010502766100_jiaf476-B87","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/apt.13414","article-title":"The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase","volume":"42","author":"Scott","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2036.11.s1.13.x","article-title":"The actions of bismuth in the treatment of Helicobacter pylori infection","volume":"11 Suppl 1","author":"Lambert","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112010502766100_jiaf476-B89","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/gutjnl-2015-311019","article-title":"Role of bismuth in improving Helicobacter pylori eradication with triple therapy","volume":"65","author":"Dore","year":"2016","journal-title":"Gut"},{"key":"2025112010502766100_jiaf476-B90","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"2025112010502766100_jiaf476-B91","doi-asserted-by":"crossref","first-page":"17562848211044064","DOI":"10.1177\/17562848211044064","article-title":"Comments regarding use of rifabutin for Helicobacter pylori eradication","volume":"14","author":"Graham","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2025112010502766100_jiaf476-B92","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/00365521.2015.1092577","article-title":"In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy","volume":"51","author":"Di Giulio","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"2025112010502766100_jiaf476-B93","doi-asserted-by":"crossref","first-page":"e12531","DOI":"10.1111\/hel.12531","article-title":"Effective antimicrobial activity of rifabutin against multidrug-resistant Helicobacter pylori","volume":"23","author":"Siavoshi","year":"2018","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B94","doi-asserted-by":"crossref","first-page":"9351801","DOI":"10.1155\/2019\/9351801","article-title":"Rifabutin and furazolidone could be the candidates of the rescue regimen for antibiotic-resistant H. pylori in Korea","volume":"2019","author":"Choi","year":"2019","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2025112010502766100_jiaf476-B95","doi-asserted-by":"crossref","first-page":"e12660","DOI":"10.1111\/hel.12660","article-title":"Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018","volume":"24","author":"Lee","year":"2019","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B96","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1186\/s12879-019-4536-8","article-title":"Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates","volume":"19","author":"Kouitcheu Mabeku","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025112010502766100_jiaf476-B97","doi-asserted-by":"crossref","first-page":"e0213868","DOI":"10.1371\/journal.pone.0213868","article-title":"Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic","volume":"14","author":"Miftahussurur","year":"2019","journal-title":"PLoS One"},{"key":"2025112010502766100_jiaf476-B98","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/IDR.S187063","article-title":"Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance","volume":"12","author":"Miftahussurur","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2025112010502766100_jiaf476-B99","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13756-019-0482-x","article-title":"Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics","volume":"8","author":"Miftahussurur","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025112010502766100_jiaf476-B100","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1053\/j.gastro.2021.02.014","article-title":"Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population","volume":"160","author":"Argueta","year":"2021","journal-title":"Gastroenterology"},{"key":"2025112010502766100_jiaf476-B101","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1053\/j.gastro.2021.07.012","article-title":"Comparison of culture with antibiogram to next-generation sequencing using bacterial isolates and formalin-fixed, paraffin-embedded gastric biopsies","volume":"161","author":"Hulten","year":"2021","journal-title":"Gastroenterology"},{"key":"2025112010502766100_jiaf476-B102","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.1093\/infdis\/jiac417","article-title":"The inappropriateness of using rifampicin E-test to predict rifabutin resistance in Helicobacter pylori","volume":"226","author":"Yang","year":"2022","journal-title":"J Infect Dis"},{"key":"2025112010502766100_jiaf476-B103","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.3390\/microorganisms11122852","article-title":"Exploring alternative treatment choices for multidrug-resistant clinical strains of Helicobacter pylori in Mongolia","volume":"11","author":"Khangai","year":"2023","journal-title":"Microorganisms"},{"key":"2025112010502766100_jiaf476-B104","doi-asserted-by":"crossref","first-page":"e13093","DOI":"10.1111\/hel.13093","article-title":"Antibiotic susceptibility pattern of Helicobacter pylori against eight antibiotics: a study from North India","volume":"29","author":"Arfi","year":"2024","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B105","doi-asserted-by":"crossref","first-page":"e70011","DOI":"10.1111\/hel.70011","article-title":"Efficacy of rifabutin-based Helicobacter pylori eradication regimen in Korea with high prevalence of tuberculosis infection","volume":"30","author":"Kim","year":"2025","journal-title":"Helicobacter"},{"key":"2025112010502766100_jiaf476-B106","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jpn3.12421","article-title":"Factors associated with Helicobacter pylori antimicrobial resistance in a US pediatric cohort","volume":"80","author":"Riaz","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025112010502766100_jiaf476-B107","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/jac\/dkm039","article-title":"Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany","volume":"59","author":"Glocker","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2025112010502766100_jiaf476-B108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000191204","article-title":"Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori","volume":"79","author":"Suzuki","year":"2009","journal-title":"Digestion"},{"key":"2025112010502766100_jiaf476-B109","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2217\/fmb-2020-0084","article-title":"Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data","volume":"15","author":"Boyanova","year":"2020","journal-title":"Future Microbiol"},{"key":"2025112010502766100_jiaf476-B110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2023.11.001","article-title":"Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan","volume":"138","author":"Kuo","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2025112010502766100_jiaf476-B111","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1128\/AAC.43.6.1497","article-title":"Rifampin and rifabutin resistance mechanism in Helicobacter pylori","volume":"43","author":"Heep","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112010502766100_jiaf476-B112","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1128\/AAC.05437-11","article-title":"Helicobacter pylori resistance to rifabutin in the last 7 years","volume":"55","author":"Nishizawa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112010502766100_jiaf476-B113","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ijantimicag.2009.12.017","article-title":"Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns","volume":"35","author":"Tupin","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2025112010502766100_jiaf476-B114","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1128\/AAC.11.5.773","article-title":"Permeability barrier to rifampin in mycobacteria","volume":"11","author":"Hui","year":"1977","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_4\/S384\/65408923\/jiaf476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/Supplement_4\/S384\/65408923\/jiaf476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T15:51:04Z","timestamp":1763653864000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/Supplement_4\/S384\/8329320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":114,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2025,11,20]]},"published-print":{"date-parts":[[2025,11,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf476","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,11,15]]}}}